Constructed a detailed forecast model of the Non-Small Cell Lung Cancer market that accounted for stage at diagnosis, patients' disease progression in both the adjuvant and metastatic settings, lines of therapy and treatment history, and genetic mutations both prior to and resulting from treatment.
Constructed population estimates for a rare genetic disorder. This then formed the foundation for a forecast model for a drug with an orphan indication, including the impact of genetic testing and gene therapy on the population.
Provided forecasting support for a currently marketed, multi-billion dollar product franchise. Integrated weekly data updates, constructed new Excel-based forecast models to improve forecasting process and accuracy for the brands, and provided support for strategic decision-making.